Loading clinical trials...
Loading clinical trials...
A Phase 1, Randomized, Open-label, Parallel-Group, Single-Dose, Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial + Syringe Presentation in Healthy Adults
Conditions
Interventions
efgartigimod PH20 SC as a prefilled syringe presentation
efgartigimod PH20 SC as a vial + syringe presentation
Locations
2
United States
Investigator site 0010209
Tempe, Arizona, United States
Investigator site 0010208
Lincoln, Nebraska, United States
Start Date
March 13, 2023
Primary Completion Date
May 12, 2023
Completion Date
May 12, 2023
Last Updated
October 31, 2023
NCT07345130
NCT06969963
NCT06924190
NCT06830954
NCT06758531
NCT06600282
Lead Sponsor
argenx
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions